Grunenthal Employs BioClinica’s Next Gen Trident IWR/IVR

Grunenthal GmbH will employ BioClinica’s next generation Trident IWR/IVR for a global pain medication study involving 350 patients at 80 sites across 17 countries. Trident will be used to streamline the clinical trials process, with the goal of making it faster and easier to set up, test, and deploy clinical study protocols.
 
Trident’s new interactive web and voice response technology replaces a manual system for managing inventory, returns, and accountability of controlled substances. Trident is designed to automate these tasks and make it easier to stay in compliance with controlled substance regulations.
 
“BioClinica listened to our needs and built the functionality we needed into their IRT system in time for our deadline,” said Henk Dieteren, associate director, head clinical supply manager of compound development and branding for clinical development operations at Clinical Trial Supply. “We envision IRT systems becoming an integral part of our controlled substance studies. Trident’s ability to manage controlled substance inventory is crucial to meet strict regulatory requirements for conducting clinical trials that involve investigative compounds related to pain management.”
 
“We are very pleased Grunenthal is expanding its use of BioClinica products to include Trident,” said Peter Benton, BioClinica’s president of eClinical Solutions. “The BioClinica suite of eClinical solutions is designed especially for this kind of integration, and will help Grunenthal manage its future clinical trials more efficiently.”